Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1

Key Points

The study aims to evaluate the role of neuropilin-1 (NRP1) in CD8+ T cells and its impact on outcomes for melanoma patients undergoing anti-PD1 therapy.
Analyzed the expression of NRP1 in CD8+ T cells from melanoma patients receiving anti-PD1 treatment.
Evaluated the correlation between NRP1 expression and patient outcomes.
Higher NRP1 expression in CD8+ T cells correlates with poorer outcomes in melanoma patients treated with anti-PD1.
NRP1 might serve as a therapeutic target to enhance the efficacy of anti-PD1 therapies.

Identifies NRP1 cooperation with PD-1 in CD8+ T cells predicts melanoma outcomes, indicating a new treatment target.

T cells predicts poor outcome of patients treated with anti-PD1. NRP1 is a promising target to overcome resistance to anti-PD1 therapies.

No takes yet. Share an insight, caveat, or question.

Rossignol et al. (2022) studied this question.

View Full Paper

Ask AI

Bookmark

Share